Why the Psychedelic Experience Is Not a Side Effect — It’s Part of the Treatment
In many conventional medical models, treatment is framed almost entirely in pharmacological terms. Psychological and experiential effects are often treated as secondary. Ibogaine therapy does not follow this model.
Clinical research and observational data suggest that the subjective, visionary experience associated with ibogaine is closely linked to its therapeutic potential. Early work by Dr. Deborah Mash noted that individuals undergoing ibogaine treatment frequently reported intense introspective experiences alongside reductions in withdrawal and craving, indicating that the experience itself may play a meaningful role in recovery (Mash et al., 2000).
At The Iboga Wellness Institute, this understanding informs a treatment philosophy that integrates medical care with psychological preparation, rather than attempting to suppress or bypass the experience itself. Learn more about our clinical approach and mission on our About Us page.
The Oneiric State: A Clinically Observed Waking Dream
During ibogaine treatment, many individuals enter what researchers describe as an oneiric or waking dream state. This phase is typically internally focused and may include vivid imagery, memory recall, and sustained introspection.
A clinical observational study examining ibogaine detoxification in individuals with opioid and cocaine dependence documented these effects alongside measurable changes in withdrawal and abstinence outcomes (Mash et al., 2018). These experiences are generally structured and coherent, distinguishing them from disorganized hallucinations associated with delirium.
Neuroimaging research conducted at Imperial College London provides additional context, showing that psychedelic compounds temporarily alter brain networks involved in rigid thought patterns, allowing for increased psychological flexibility (Carhart-Harris et al., 2012).
You can explore how this process fits into treatment by reviewing our Detoxification Program and Our Programs pages.
Why Visionary Experiences Can Support Addiction Recovery
Addiction is not only a physical condition; it is reinforced by deeply ingrained behavioral and emotional patterns. Research in psychedelic-assisted therapy consistently shows that insight-driven experiences are associated with improved long-term outcomes.
A well-known clinical study from Johns Hopkins University found that the intensity and personal meaning of psychedelic experiences were strongly correlated with sustained abstinence in addiction treatment (Garcia-Romeu et al., 2014).
In ibogaine therapy, individuals often report gaining clarity about the consequences of addiction, recognizing destructive cycles, and developing renewed motivation for change. These insights are addressed through structured follow-up and support within programs such as our Medical Conditions Program and Mental Health Program.
Safety, Screening, and Clinical Responsibility
A responsible clinical discussion of ibogaine must include safety considerations. Peer-reviewed literature highlights both ibogaine’s potential benefits and the importance of medical screening and monitoring, particularly regarding cardiac risk (Alper et al., 2018).
At The Iboga Wellness Institute, safety is treated as a foundational element of care, with protocols designed to assess medical eligibility and reduce risk. More information about our standards can be found on our Safety page and within our broader Research resources.
Integration: Turning Insight Into Sustainable Change
The ibogaine experience is not the endpoint of treatment. Integration is essential for translating insight into lasting behavioral change.
A clinically sound approach views ibogaine as a catalyst — one that may interrupt dependence and surface psychological insight, but requires structured support afterward to sustain recovery. This philosophy is embedded across our programs and informed by both clinical research and traditional knowledge, which you can explore further through The Iboga Story.
References & Further Reading
- Mash, D. C., et al. (2000). Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences.
https://europepmc.org/abstract/MED/11085338 - Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology.
https://europepmc.org/article/MED/29922156 - Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
https://europepmc.org/article/MED/25563443 - Carhart-Harris, R. L., et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS.
https://pubmed.ncbi.nlm.nih.gov/22308440/ - Alper, K., et al. (2018). Ibogaine as a treatment for substance misuse: potential benefits and practical dangers. https://europepmc.org/article/MED/30471681











